Leuthold Group’s United Therapeutics UTHR Stock Holding History

Leuthold Group’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.52M	Sell	10,184 -552	-5%	-$311K	0.55%	75
2026 Q1	$6.37M	Buy	10,736 +64	+0.6%	+$31.9K	0.68%	51
2025 Q4	$5.2M	Buy	10,672 +3,126	+41%	+$1.46M	0.56%	69
2025 Q3	$3.16M	Buy	+7,546	New	+$2.54M	0.35%	110
2016 Q2	–	Sell	-31,789	Closed	-$3.54M	–	248
2016 Q1	$3.54M	Buy	31,789 +632	+2%	+$80K	0.39%	99
2015 Q4	$4.88M	Buy	31,157 +1,457	+5%	+$212K	0.51%	80
2015 Q3	$3.9M	Sell	29,700 -3,783	-11%	-$607K	0.41%	93
2015 Q2	$5.82M	Buy	33,483 +1,508	+5%	+$271K	0.54%	57
2015 Q1	$5.51M	Buy	31,975 +113	+0.4%	+$17.2K	0.51%	70
2014 Q4	$4.13M	Buy	+31,862	New	+$4.11M	0.41%	93
2013 Q4	–	Sell	-13,420	Closed	-$1.06M	–	293
2013 Q3	$1.06M	Sell	13,420 -1,618	-11%	-$118K	0.1%	224
2013 Q2	$990K	Buy	+15,038	New	+$969K	0.09%	239

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Leuthold Group's UTHR Position: Q2 2026 in Review

Leuthold Group reduced its United Therapeutics (UTHR) stake by 5.1% in Q2 2026, selling an estimated $311K and leaving 10,184 shares worth $5.52M. The position accounts for 0.55% of the portfolio, ranked #75.

Leuthold Group first reported a position in UTHR in Q2 2013 and has held it in 12 quarters since. The position peaked at $6.37M in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Leuthold Group held 10,184 shares of United Therapeutics worth $5.52M as of Q2 2026.
Leuthold Group sold 552 United Therapeutics shares in Q2 2026, an estimated $311K.
United Therapeutics made up 0.55% of Leuthold Group's portfolio in Q2 2026, its #75 holding.
Leuthold Group first reported a position in United Therapeutics in Q2 2013 and has held it in 12 quarters since.
Leuthold Group's United Therapeutics position peaked at $6.37M in Q1 2026.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Leuthold Group's 13F filing for Q2 2026, filed 4 Aug 2026.